Sensei Biotherapeutics Reports Full Year 2025 Financial Results

Biotech firm shares details on annual performance and corporate updates.

Mar. 30, 2026 at 6:08pm

Got story updates? Submit your updates here. ›

Sensei Biotherapeutics, a Nasdaq-listed biotech company based in Boston, has reported its full-year 2025 financial results, highlighting key developments and performance metrics from the previous year.

Why it matters

As a publicly traded biotech firm, Sensei's annual financial reporting provides important insights into the company's progress, pipeline, and overall health, which can impact investor sentiment and the broader life sciences industry.

The details

In its report, Sensei Biotherapeutics shared details on its financial performance, including revenue, expenses, and net income or loss. The company also provided updates on the status of its drug development programs and other corporate initiatives undertaken during 2025.

  • Sensei Biotherapeutics reported its full-year 2025 financial results on March 30, 2026.

The players

Sensei Biotherapeutics, Inc.

A Nasdaq-listed biotech company based in Boston that is focused on the development of novel immunotherapies for cancer and other diseases.

Got photos? Submit your photos here. ›

The takeaway

Sensei Biotherapeutics' annual financial report provides a window into the company's performance and progress, which is important for investors, industry analysts, and the broader biotech community to monitor as the firm continues to advance its drug pipeline and corporate strategy.